In the end, less than nine months after Fauci’s comments, Pfizer and BioNTech’s vaccine became the first vaccine to gain approval from the UK regulator. A few weeks later, the AstraZeneca and Oxford vaccines were given the green light.
But, where the former has received warm applause and is now one of the most widely used in high-income countries, the AstraZeneca jab remains marred by early reviews.
Earlier this year, discussions focused on its potential link to blood clots. However, an article this week suggested that patients bitten by AstraZeneca develop blood clots at a “similar rate” to those who received the Pfizer vaccine.
“I think this paper looks pretty good,” said Sir John. “We haven’t seen a big problem with blood clots in Latin America, in Southeast Asia, and we haven’t seen a lot of blood clots in Africa.
“There is an interesting question as to whether there is a differential responsibility for blood clots among Caucasians from Northern Europe in Norway, where they first appeared, compared to everyone else. ”